

Special Issue

Research in Innate and Adaptive Immunity

Message from the Guest Editors

Complex cellular and humoral networks of adaptive immune cells and metabolic products are well known. However, fundamental questions remain unanswered about the interconnexion between innate and adaptive immune response(s) to immunoevasion. These will improve our knowledge on immunometabolic diseases, cancer, virus clearance, and recovery of immunocompetence. Identification and development of those with a concerted perspective will overcome the usually fragmented and compartmentalized approach to addressing the underlying immune alterations. Integrating both components in the context of its relationship to exposures (i.e., diet, environment, microbiota) and the host's intrinsic and modifiable factors and disease outcomes will contribute toward vaccine and immunotherapeutic design and evaluation.

Guest Editors

Dr. Jose Moisés Laparra

Molecular Immunonutrition Group, Madrid Institute for Advanced Studies in Food (IMDEA-Food), 28049 Madrid, Spain

Dr. Juan Antonio Giménez-Bastida

Laboratory of Food and Helath, Research Group on Quality, Safety and Bioactivity of Plant Foods, Department Food Science and Technology, CEBAS-CSIC, P.O. Box 164, Campus de Espinardo, 30100 Murcia, Spain

Deadline for manuscript submissions

30 June 2025



Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



mdpi.com/si/120629

Vaccines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the second half of 2024).